trending Market Intelligence /marketintelligence/en/news-insights/trending/j2LhEJFJxrGNP2rIkjax8w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In This List

US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

S&P Global Market Intelligence

Cannabis Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

The U.S. Food and Drug Administration needs more time to review Flexion Therapeutics Inc.'s supplemental new drug application for Zilretta beyond the expected Oct. 14 decision date.

Zilretta was approved to treat osteoarthritis knee pain in 2017. The Burlington, Mass.-based biotechnology company has asked the FDA to revise Zilretta's label to include results from a Phase 3b clinical trial that evaluated repeated doses of the drug in patients with osteoarthritis knee pain.

The regulator did not provide a new date for the decision, but said the review is expected to be completed in the next few weeks, according to Flexion's Oct. 14 press release. Flexion also said the agency has not asked for any additional information to supplement the application.

Flexion develops anti-inflammatory and pain management therapies for patients with musculoskeletal conditions.